» Articles » PMID: 35301654

Differentially Expressed Plasmatic MicroRNAs in Brazilian Patients with Coronavirus Disease 2019 (COVID-19): Preliminary Results

Abstract

Background: Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is known that host microRNAs (miRNAs) can be modulated to favor viral infection or to protect the host. Herein, we report preliminary results of a study aiming at identifying differentially expressed plasmatic miRNAs in Brazilian patients with COVID-19.

Methods And Results: miRNAs were extracted from the plasma of eight patients with COVID-19 (four patients with mild COVID-19 and four patients with severe/critical COVID-19) and four healthy controls. Patients and controls were matched for sex and age. miRNA expression levels were detected using high-throughput sequencing. Differential miRNA expression and enrichment analyses were further evaluated. A total of 18 miRNAs were differentially expressed between patients with COVID-19 and controls. miR-4433b-5p, miR-6780b-3p, miR-6883-3p, miR-320b, miR-7111-3p, miR-4755-3p, miR-320c, and miR-6511a-3p were the most important miRNAs significantly involved in the PI3K/AKT, Wnt/β-catenin, and STAT3 signaling pathways. Moreover, 42 miRNAs were differentially expressed between severe/critical and mild patients with COVID-19. miR-451a, miR-101-3p, miR-185-5p, miR-30d-5p, miR-25-3p, miR-342-3p, miR-30e-5p, miR-150-5p, miR-15b-5p, and miR-29c-3p were the most important miRNAs significantly involved in the Wnt/β-catenin, NF-κβ, and STAT3 signaling pathways.

Conclusions: If validated by quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) in a larger number of participants, the miRNAs identified in this study might be used as possible biomarkers for the diagnosis and severity of COVID-19.

Citing Articles

Circulatory microRNAs as potential biomarkers for different aspects of COVID-19.

Zali M, Sadat Larijani M, Bavand A, Moradi L, Ashrafian F, Ramezani A Arch Virol. 2024; 170(1):8.

PMID: 39666114 DOI: 10.1007/s00705-024-06184-3.


Longitudinal transcriptome analysis reveals distinct gene expression patterns in traditional Chinese medicine syndromes of upper respiratory tract infections.

Zou H, Huang C, Feng Q, Yu B, Liu J, Shu X Front Genet. 2024; 15:1483098.

PMID: 39659674 PMC: 11628533. DOI: 10.3389/fgene.2024.1483098.


Circulating miRNAs in the Plasma of Post-COVID-19 Patients with Typical Recovery and Those with Long-COVID Symptoms: Regulation of Immune Response-Associated Pathways.

Timofeeva A, Nikitin A, Nevinsky G Noncoding RNA. 2024; 10(5).

PMID: 39311385 PMC: 11417918. DOI: 10.3390/ncrna10050048.


The relationship between microRNAs and COVID-19 complications.

Kebriaei A, Besharati R, Namdar Ahmad Abad H, Havakhah S, Khosrojerdi M, Azimian A Noncoding RNA Res. 2024; 10:16-24.

PMID: 39296641 PMC: 11406673. DOI: 10.1016/j.ncrna.2024.08.007.


Characterization of the SARS-CoV-2 Genome 3'-Untranslated Region Interactions with Host MicroRNAs.

Frye C, Cunningham C, Mihailescu M ACS Omega. 2024; 9(34):36148-36164.

PMID: 39220490 PMC: 11360049. DOI: 10.1021/acsomega.4c01050.


References
1.
Lu H, Stratton C, Tang Y . Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020; 92(4):401-402. PMC: 7166628. DOI: 10.1002/jmv.25678. View

2.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

3.
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M . The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020; 53:25-32. PMC: 7211650. DOI: 10.1016/j.cytogfr.2020.05.003. View

4.
Jean S, Lee P, Hsueh P . Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020; 53(3):436-443. PMC: 7129535. DOI: 10.1016/j.jmii.2020.03.034. View

5.
Young Chung J, Thone M, Kwon Y . COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2020; 170:1-25. PMC: 7759095. DOI: 10.1016/j.addr.2020.12.011. View